Spark Therapeutics
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Richard Staines
M&A, Rare diseases, Roche, Spark Therapeutics
0 Comment
R&D/ R&D/ Views & Analysis/ Views and analysis
R&D Roundup: Pharma gets in on the biotech boom
George Underwood
Alexion, Alnylam, Biotech, Cell Mogrify, Novartis, R&D, Roche, Spark Therapeutics, UK
0 Comment
Roche insists Spark deal is still on, despite lacklustre take-up
Phil Taylor
gene therapy, Luxturna, Roche, Spark Therapeutics
0 Comment
Spark/Novartis eye gene therapy nears EU market – but at what price?
Richard Staines
Novartis, ophthalmology, Rare diseases, Spark Therapeutics
0 Comment
Spark shares tank after haemophilia gene therapy safety signal
Richard Staines
gene therapy, Rare diseases, Spark Therapeutics
0 Comment
Biotech still pressing on with late stage trials
Pfizer moves haemophilia gene therapy into phase 3
Piotr Wnuk
haemophilia, haemophilia B, Pfizer, Spark Therapeutics
0 Comment
News/ Partner content/ Press releases
Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 2018
Pavan Solanki
alimera, elasmogen, ophthalmic, ophthalmology, Spark Therapeutics
0 Comment
Ophthalmic Drugs Conference London
Priority review voucher prices fall again after Spark’s $110m sale
Richard Staines
Jazz Pharmaceuticals, ophthalmology, Rare diseases, Spark Therapeutics
0 Comment
Voucher prices have fallen since their 2015 peak